前へ
次へ

Corporate Profile

Biocomo Incorporation is engaged in development of innovative biological vaccines.
Its missions are to create infectious vaccines that the human being have not overcome such as RSV and Ebola and to create most efficient, cost effective and safe cancer vaccines utilizing its high immunogenicity characteristics.

more

Technology

BC-PIV is our core platform technology which was named after our corporate name, BioComo and our leading vaccine carrier is derived from the recombinant human parainfluenza virus 2 (hPIV2) vectors.

more

Pipeline

Biocomo can offer specific candidates in infectious vaccines and cancer vaccines.

more

Information

2017-10
Biocomo will present a poster, titled as “A structure based vaccine by a non-transmissible human parainfluenza virus vector” at 2017 International Society for Vaccines (ISV) Annual Congress at the Institute Pasteur in Paris on October 5th ? 7th
2017-07
The US patent, titled as “Vaccine Prepared Utilizing Human Parainfluenza Virus Type 2 Vector” was granted on June 4, 2017
2017-06
The European Patent titled as “method for producing virus vector gene transfer” was granted on June 14, 2017.
2016-01
Biocomo participated in Biotech Showcase in San Francisco
2015-11
BioComo exhibited at Bio Europe.
2015-10
Bioomo exhibited at Bio Japan.
  • banner
Page Top